Bricor

Prevention of thrombotic events (CV death, MI & stroke) in patients w/ acute coronary syndromes (unstable angina, non-ST elevation MI or ST elevation MI) including patients managed medically, & those who are managed w/ percutaneous coronary intervention or CABG.

Initially 180 mg as single loading dose (2 tab of 90 mg) & then continued at 90 mg bid. Duration of treatment: At least 12 mth. May be given in combination w/ ASA 75-150 mg daily (unless specifically contraindicated). Switching from clopidogrel to ticagrelor Administer 1st dose of ticagrelor 90 mg 24 hr following last dose of clopidogrel.

May be taken with or without food: For patients w/ swallowing difficulties, crush tab to a fine powd & mix in ½ glass of water. Drink immediately. Rinse glass w/ another ½ glass of water & drink. Mixt may be administered via a nasogastric tube (≥CH8). Flush tube w/ water after administration.

Hypersensitivity. Active pathological bleeding. History of intracranial haemorrhage. Severe hepatic impairment.

Increased risk for bleeding in patients w/ a propensity to bleed (eg, due to recent trauma, recent surgery, active or recent GI bleeding, or moderate hepatic impairment) or who are at increased risk of trauma; concomitant use of drugs that may increase risk of bleeding (eg, NSAIDs, oral anticoagulants &/or fibrinolytics w/in 24 hr of ticagrelor). Patients who require surgery. Discontinue treatment 5 days prior surgery in patients to undergo elective surgery & if antiplatelet effect is not desired. Increased risk of bradycardic events (eg, patients w/o pacemaker w/ sick sinus syndrome, 2nd- or 3rd-degree AV block or bradycardic-related syncope). Dyspnoea. Not recommended w/ high maintenance dose of ASA (>300 mg). Avoid co-administration w/ strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, nefazodone, ritonavir, & atazanavir). Avoid premature discontinuation of treatment. Moderate hepatic impairment. Pregnancy. Not recommended during lactation. Childn <18 yr.

Blood disorders, bleeding; hyperuricaemia; dyspnoea. Gout; dizziness, syncope; vertigo; hypotension; resp system bleedings; GI haemorrhage, diarrhoea, nausea; SC or dermal bleeding, pruritus; urinary tract bleeding; increased blood creatinine; post procedural haemorrhage, traumatic bleedings.

Increased C_max & AUC w/ ketoconazole, other strong CYP3A4 inhibitors (eg, clarithromycin, nefazodone, ritonavir, atazanavir); diltiazem, other moderate CYP3A4 inhibitors (eg, amprenavir, aprepitant, erythromycin, fluconazole, verapamil); cyclosporine. Decreased C_max & AUC w/ rifampin & other CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarb). Increased C_max & AUC of simvastatin, atorvastatin & digoxin.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AC24 - ticagrelor ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.

Rx